Agenus (NASDAQ:AGEN)‘s stock had its “buy” rating reaffirmed by research analysts at Maxim Group in a report released on Monday,American Banking News.com reports. Agenus Inc (NASDAQ:AGEN) shares after opening at $3.21 moved to $3.31 on last trade day and at the end of the day closed at $4.42. Company price to sales ratio in past twelve months was calculated as 68.59 and price to cash ratio as 7.51. Agenus Inc (NASDAQ:AGEN) showed a negative weekly performance of -0.30%.
JPMorgan Chase & Co. raised their price target on Agios Pharmaceuticals (NASDAQ:AGIO) stock from $35.00 to $40.00, ARN reports. The company traded as high as $41.33 and last traded at $40.67, with a volume of 165,895 shares changing hands. The stock had previously closed at $37.02. Agios Pharmaceuticals Inc (NASDAQ:AGIO) shares fell -4.52% in last trading session and ended the day on $37.38. AGIO return on equity ratio is recorded as -193.90% and its return on assets is -31.90%.
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by Zacksfrom a “neutral” rating to an “underperform” rating in a research note issued on Tuesday, Analyst Ratings News reports. They currently have a $2.40 price target on the stock. Zacks‘s price objective suggests a potential downside of 6.61% from the company’s current price. Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares moved down -1.45% in last trading session and was closed at $2.04, while trading in range of $2.03-$2.24. Amicus Therapeutics, Inc. (NASDAQ:FOLD) year to date performance is -13.19%.
Regulus Therapeutics (NASDAQ:RGLS) had its price target increased by Needham & Company to $14.00 in a research report sent to investors on Friday morning, Analyst Ratings News reports. Regulus Therapeutics Inc (NASDAQ:RGLS) weekly performance is -3.48%. On last trading day company shares ended up $8.59. Regulus Therapeutics Inc (NASDAQ:RGLS) distance from 50-day simple moving average is -11.30%. Analysts mean target price for the company is $15.50.